Overview

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Status:
Recruiting

Trial end date:
2022-07-29

Target enrollment:

Participant gender:

Summary

Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent patients with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD

Phase:

Phase 3

Details

Lead Sponsor:

H. Lundbeck A/S

Treatments:

Vortioxetine